It is no secret that pharmaceutical companies are being blamed left, right and center for rising healthcare costs. A series of high-profile cases, including Turing Pharmaceuticals’ 5,000% price increase of its Toxoplasmosis drug, Daraprim, and [...]

When Sarepta Therapeutics’ Duchene muscular dystrophy (DMD) drug, Exondys 51, got the green light from the US FDA last September, it became most controversial drug approvals of 2016. FDA Commissioner at the time, Robert Califf, [...]

This week, it was announced that the Republicans failed to pass the American Health Care Act (AHCA), which was poised to replace Obama’s Affordable Care Act. However, this does not mean that efforts to improve [...]

This week, Rare Disease Day 2017 was celebrated in over 90 countries around the world, to help raise awareness of the 350 million people currently living with a rare disease. In honor of this day, [...]

Maryland Pricing Transparency Bill - One of the biggest issues for the biopharma industry in 2016 was the growing public backlash against rising drug prices. It seems the public have had enough of drug companies [...]

It is no secret that President Trump is trying to shake up the Healthcare system in the US. After being sworn into office earlier this year, he has taken initial steps to repeal the Affordable [...]

Since Britain voted to leave the EU, there has been much speculation on how this decision will affect the pharmaceutical industry and healthcare system within the country. Proponents of Brexit remain optimistic. However, there are [...]

In 2016, Sarepta Therapeutics was given the green light by the FDA for its Duchenne muscular dystrophy (DMD) drug, Exondys 51. It was a huge win for the DMD patient community, as it was the [...]

For many patients in the US, the passing of the 21st Century Cures Act was a great success. This new law will allow Real World Data (RWD) and patient experiences to be to be included [...]

There is still a lot of uncertainty about how the Trump administration will affect the biopharma industry. Some companies are hoping Trump's promise to remove 75-80% of regulation will help them get their drugs to [...]